Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2018
At a glance
- Drugs CAR-CLD18-T-cells-Carsgen-Therapeutics (Primary)
- Indications Adenocarcinoma; Gastric cancer; Pancreatic cancer
- Focus Adverse reactions
- 07 Sep 2018 According to a CARsgen media release, data from this trial were presented at 2018 CAR-TCR Summit.
- 07 Sep 2018 Results published in the CARsgen Media Release
- 08 Mar 2018 Status changed from not yet recruiting to recruiting.